Comparison of DOS and Windows version of the MwPharm - a pharmacokinetic software for PK/PD monitoring of digoxin

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F20%3AE0108671" target="_blank" >RIV/00843989:_____/20:E0108671 - isvavai.cz</a>

Result on the web

<a href="https://www.klinickafarmakologie.cz/pdfs/far/2020/04/01.pdf" target="_blank" >https://www.klinickafarmakologie.cz/pdfs/far/2020/04/01.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Comparison of DOS and Windows version of the MwPharm - a pharmacokinetic software for PK/PD monitoring of digoxin

Original language description

Background and objectives: Digoxin is the oldest drug indicated for the treatment of systolic heart failure (HF). It is also useful in controlling excessive ventricular rate in the presence of atrial arrhythmias. Therapeutic drug monitoring (TDM) has become an integral part of its prescription, allowing to optimize therapy and to reduce the incidence of toxicity. Since 1991, the MwPharm software package (Mediware, Groningen, The Netherlands / Prague, Czech Republic) has been used for pharmacokinetic and pharmacodynamic (PK/PD) modelling in TDM, including digoxin. First Windows version with a broader spectrum was released in 2014, as a reaction of worse support of the DOS background on later versions of Windows. After its release, the company had decided to not develop DOS versions anymore, even though they are globally used with success. The aim of this study was to compare the usefulness of DOS and Windows version (WIN) of the MwPharm, and their prediction quality in TDM of digoxin. Materials and methods: 29 patients (23 with multidrug treated systolic HF, 4 with atrial fibrillation, 1 pregnant woman treated due to fetus tachycardia, 1 infant with Tetralogy of Fallot) who were treated for > 1 month with digoxin were eligible for inclusion. Patients received digoxin (Digoxin Léčiva®?, Zentiva, Prague, Czech Republic) in a median dose 0.125 mg (range 0.063–0.250 mg) once daily. The therapeutic range for digoxin was established at 0.5–2.0 µg/l, according to manufacturer requirements. Both MwPharm versions (DOS version – MwPharm 3.30, Windows version – MwPharm++ 1.3.5) were used to parameterize the po- pulation PK model. Serum digoxin concentrations (SDC) were repeatedly examined and the differences between measured and calculated values predicted by both versions, including the percentage prediction error (%PE), were compared. Results: SDC were obtained from 29 patients (mean age 67±20 years, body weight 72±27 kg). WIN, compared to DOS, used lower constants for abs...

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Klinická farmakologie a farmacie

ISSN

1212-7973

e-ISSN

1803-5353

Volume of the periodical

34

Issue of the periodical within the volume

4

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

6

Pages from-to

152-157

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85101977251